Teicoplanin, also known as Taicomycin, was first discovered in 1975. It is a glycopeptide antibiotic obtained by fermentation and artificial extraction of specific actinomycetes. The molecular formula is CHCN33; it is off-white to pale yellow freeze-dried Blocks and powders, sealed and stored below 10°C; mainly used for the treatment of various serious Gram-positive (G+) bacterial infections.
1.Pharmacological effects
(1) Treatment: It is used for staphylococcal infections that cannot be treated with penicillin and cephalosporin antibiotics or that have failed treatment and are resistant to other antibiotics.
(2) Sensitive bacteria: Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus, Enterococcus, Corynebacterium, Clostridium difficile, Peptostreptococcus, etc.
(3) Infection: used for skin, soft tissue, urinary tract, respiratory tract, bone and joint infections, sepsis, endocarditis and peritonitis associated with continuous ambulatory peritoneal dialysis.
(4) Prevention: When orthopedic surgery has high risk factors for gram-positive bacterial infection; replacement therapy is used as an alternative to vancomycin and metronidazole.
2. Mechanism of action
The mechanism of action of teicoplanin is to inhibit the synthesis of cell wall and interfere with the synthesis of peptidoglycan; the drug binds to the bacterial cell wall mucopeptide in the division and reproduction stage, and the binding point is the aminoacyl-D-alanyl-D at the end of the mucopeptide. -Alanine, thereby preventing the synthesis of bacterial cell wall membranes to inhibit and kill bacteria.
Minkai Bio Co., Ltd. is committed to the production of biomedicine and a variety of high-end generic drugs and innovative drugs. It is a supplier of teicoplanin. Welcome to our website.
